

OCTOBER 16-19, 2024
CHICAGO, ILLINOIS



Chicago Specials

Fall Group Meeting

Gastrointestinal Committee

Gastrointestinal Committee

Leadership

Chair: Philip A. Philip, MD, PhD, FRCP
 Vice-Chair: Elena G. Chiorean, MD
 Executive Officer: Christopher W. Ryan, MD
 Statisticians: Katherine A. Guthrie, PhD
 Sarah Colby, MS
 Allison Hayes, BS

Scientific Leadership

Gastroesophageal: Syma Iqbal, MD
 Zev A. Wainberg, MD
 Pancreatic: Davendra P.S. Sohal, MD
 Andrew M. Lowy, MD (Surgical representative)
 Hepatobiliary: Anthony B. El-Khoueiry, MD
 Rachna T. Shroff, MD
 Syed A. Ahmad, MD (Surgical representative)
 Colon: Marwan G. Fakih, MD
 Philip J. Gold, MD
 Sepideh Gholami, MD (Surgical representative)
 Neuroendocrine Tumors: Nageshwara Arvind Dasari, MD
 Jonathan R. Strosberg, MD
 Ano-Rectal: Lisa A. Kachnic, MD
 Hagen F. Kennecke, MD
 Imaging: Anthony F. Shields, MD, PhD
 Pathology: Mary Kay Washington, MD, PhD
 Radiation Oncology: Lisa A. Kachnic, MD
 Surgery: Stephen W. Behrman, MD
 Syed A. Ahmad, MD
 Flavio Rocha, MD
 Translational Medicine: Gabriel N. Duda, PhD, DMD
 Maheswari Senthil, MD

Designates

Cancer Control Liaisons: Jason A. Zell, DO (Prevention)
 Afsaneh Barzi, MD (CCD)
 Community Liaisons: Gary L. Buchsacher, MD, PhD (Medical Oncology)
 Mohamed E. Salem, MD (Medical Oncology)
 Flavio Rocha, MD (Surgical)
 David Horowitz, MD (Radiation Oncology)
 DEI Champion: Colmar Figueroa-Moseley, PhD, MPH
 Rachael Ann Safyan, MD
 Digital Engagement: Heloisa Soares, MD, PhD
 Veterans Affairs: Rangaswamy Govindarajan, MD
 Data Coordinators: Alex Rangel, BS
 Brian Zeller
 Christine Magner

Oncology Research Professionals:

CRA: TBD
 Nurse: TBD
 Patient Advocate (Pancreatic): Carole Seigel, MBA
 Patient Advocate (Colon): Marielle McLeod, MHA, CPN
 Pharmaceutical Science: Jane E. Rogers, PharmD
 Safae Chouraichi, PharmD
 Protocol Project Manager: Andrea Garcia
 Clinical Trials Program Manager: Laura Gildner, MS

Time/Location

Friday, October 18, 2024 4:30 p.m. - 6:30 p.m.
 Room: Regency D (Ballroom Level, West Tower)

Agenda

1. Welcome
2. Announcements & Introductions Philip Philip
E. Gabriela Chiorean
3. HEARD Subcommittee Initiatives Rachel Safyan, Colmar Figueroa-
Moseley, Carole Seigel, Marielle McLeod
4. SWOG Led Trials Updates

a. S1922	Michael Overman
b. S2001	Vincent Chung
c. S2104	Heloisa Soares/S. Ahmad
d. S2107	Van Morris
e. S2012	David Zhen/E. Gabriela Chiorean
f. S2303	Anwaar Saeed/Paul Oberstein
5. SWOG Co-Led Trials Updates

a. A022102	Paul Oberstein
b. A022104	Arvind Dasari
c. A022001	Heloisa Soares
d. A022101	Sepideh Gholami
e. A021804	Charles Lopez
f. A021806	Steve Behrman
g. EA2192	Philip Philip/E. Gabriela Chiorean
h. EA2183	David Horowitz
i. EA2197	Flavio Rocha
j. EA2176	Van Morris
k. EA2182	J. Murphy
l. NRG-GI003	A. El-Khoueiry
m. NRG-GI004	Michael Overman
n. CCTG NE1	Aman Chauhan

Gastrointestinal Committee

- | | |
|--|--|
| 6. Pancreatic
a. Major recent clinical results
b. NCTN trials update
c. Future SWOG plans | Davendra Sohal, Andrew Lowy |
| 7. Anal and Rectal
a. Major recent clinical results
b. NCTN trials update
c. Future SWOG plans | Hagen Kennecke, Lisa Kachnic |
| 8. Colon

a. Major recent clinical results
b. NCTN trials update
c. Future SWOG plans | Marwan Fakh, Philip Gold,
Sepideh Gholami |
| 9. Gastroesophageal
a. Major recent clinical results
b. NCTN trials update
c. Future SWOG plans | Syma Iqbal, Zev Wainberg |
| 10. Hepatobiliary

a. Major recent clinical results
b. NCTN trials update
c. Future SWOG plans | Anthony El-Khoueiry
Rachna Shroff |
| 11. Neuroendocrine
a. Major recent clinical results
b. NCTN trials update
c. Future SWOG plans | Arvind Dasari, Aman Chauhan |
| 12. Discussion/Other business | |
| 13. Adjourn | |

Gastroesophageal

Active Studies

S2303, "Randomized Phase II/III Trial of 2nd Line Nivolumab + Paclitaxel + Ramucirumab versus Paclitaxel + Ramucirumab in Patients with PD-L1 CPS \geq 1 Advanced Gastric and Esophageal Adenocarcinoma (PARAMUNE)", Dr. Saeed. Activated: 5/6/24

CTSU/A022102, "Randomized Phase III Trial of mFOLFIRINOX +/- Nivolumab vs. FOLFOX +/- Nivolumab for First-Line Treatment of Metastatic HER2-Negative Gastroesophageal Adenocarcinoma." Dr. Oberstein. Activated: 1/17/19.

CTSU/EA2174, "A Phase II/III Study of Peri-Operative Nivolumab and Ipilimumab in Patients with Locoregional Esophageal and Gastroesophageal Junction Adenocarcinoma." Dr. Kelly. Activated: 1/17/19. Temporarily Closed to Accrual as of 12/29/22.

CTSU/EA2183, "A Phase III Study of Consolidative Radiotherapy in Patients with Oligometastatic HER2 Negative Esophageal and Gastric Adenocarcinoma (EGA)." Dr. Horowitz. Activated: 2/6/20.

Pancreatic

Developing Studies

S2433, "Randomized Phase II Study of Second-Line Chemotherapy with or without Panitumumab for Locally Advanced or Metastatic KRAS/BRAF V600E Wild Type Pancreatic Adenocarcinoma." Dr. Safyan.

Active Studies

S2001, "Randomized Phase II Clinical Trial of Olaparib + Pembrolizumab Alone as Maintenance Therapy in Metastatic Pancreatic Cancer Patients with Germline BRCA1 or BRCA2 Mutations." Dr. Chung. Activated: 12/4/20.

CTSU/A021804, "A Prospective, Multi-Institutional Phase II Trial Evaluating Temozolomide vs. Temozolomide and Olaparib for Advanced Pheochromocytoma and Paraganglioma." Dr. C. Lopez. Activated: 11/2/20.

CTSU/A021806, "A Phase III Trial of Perioperative Versus Adjuvant Chemotherapy for Resectable Pancreatic Cancer." Dr. Noel. Activated: 7/1/20.

CTSU/EA2192, "APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Adjuvant Chemotherapy in Patients with Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation." Drs. Chiorean and Philip. Activated: 4/29/21.

Closed Studies

EA2186, "A Randomized Phase II Study of Gemcitabine and Nab-Paclitaxel Compared with 5-Fluorouracil, Leucovorin, and Liposomal Irinotecan in Older Patients with Treatment Naïve Metastatic Pancreatic Cancer (GIANT)." Activated: 6/18/20. Dr. Zhen. Closed to Accrual as of 10/17/23

Neuroendocrine

Active Studies

S2104, "Randomized Phase II Trial of Postoperative Adjuvant Capecitabine and Temozolomide versus Observation in High-Risk Pancreatic

Gastrointestinal Committee

Neuroendocrine Tumors." Dr. Soares. Activated: 10/14/21

S2012, "Randomized Phase II/III Trial of First Line Platinum/Etoposide with or without Atezolizumab (NSC #783608) in Patients with Advanced or Metastatic Poorly Differentiated Extrapulmonary Neuroendocrine Carcinomas (NEC)" Activated Drs. D. Zhen, E. Chiorean, E. Burgess, E. Swisher, L. Byers. Activated: 12/2/21

Closed Studies

CTSU/A021602, "Randomized Double-Blinded Phase III Study of CABozantinib versus Placebo IN Advanced Neuroendocrine Tumors after Progression on Prior Therapy (CABINET)." Dr. Strosberg. Activated: 7/18/18. Closed to Accrual as of 9/8/23

Hepatobiliary

Active Studies

CTSU/NRG-GI003, "A Phase III Randomized Trial of Protons Versus Photons for Hepatocellular Carcinoma." Dr. El-Khoueiry. Activated: 6/21/17.

CTSU/EA2197, "Optimal Perioperative Therapy for Incidental Gallbladder Cancer (OPT-IN): A Randomized Phase II/III Trial." Dr. Rocha. Activated: 12/22/20.

Closed Studies

S1815, "A Phase III Randomized Trial of Gemcitabine, Cisplatin, and Nab-Paclitaxel Versus Gemcitabine and Cisplatin in Newly Diagnosed, Advanced Biliary Tract Cancers." Dr. Shroff. Activated: 12/3/18. Permanently Closed: 2/15/21.

CTSU/EA2187, "A Phase 2 Study of Pevonedistat in Combination with Carboplatin and Paclitaxel in Advanced Intrahepatic Cholangiocarcinoma." Dr. Stein. Activated: 1/31/20. Permanently Closed: 3/22/23.

Colorectal

Active Studies

S2107, "Randomized Phase II Trial of Encorafenib and Cetuximab with or without Nivolumab for Patients with Microsatellite Stable, BRAFV600E Metastatic Colorectal Cancer." Dr. Morris. Activated: 6/6/22.

A022101, "A Pragmatic Randomized Phase III Trial Evaluating Total Ablative Therapy for Patients with Limited Metastatic Colorectal Cancer: Evaluating Radiation, Ablation, and Surgery (ERASur)" SWOG Champion: S. Gholami Activated: 1/10/23.

CTSU/NRG-GI008, Colon Adjuvant Chemotherapy Based on Evaluation

of Residual Disease (CIRCULATE-US) SWOG GI Committee Co-Chairs: P. Philip & C. Eng Activated: 3/10/22

CTSU/NRG-GI005, "Phase II/III Study of Circulating Tumor DNA as a Predictive Biomarker in Adjuvant Chemotherapy in Patients with Stage IIA Colon Cancer (COBRA)." Dr. Scott. Activated: 12/16/19.

CTSU/NRG-GI004/ S1610, "Colorectal Cancer Metastatic dMMR/MSI-H Immuno-Therapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/Bevacizumab/Atezolizumab Combination versus Single Agent Atezolizumab in the First-Line Treatment of Patients with Deficient DNA Mismatch Repair (dMMR)/Microsatellite Instability-High (MSI-H) Metastatic Colorectal Cancer." Dr. Overman. Activated: 11/7/17.

Closed Studies

S1613, "A Randomized Phase II Study of Trastuzumab and Pertuzumab (TP) Compared to Cetuximab and Irinotecan (CETIRI) in Advanced/Metastatic Colorectal Cancer (MCRC) with HER-2 Amplification." Dr. Raghav. Activated: 10/19/17. Step 3 permanently closed: 11/30/23

S0820, "A Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients with Stage 0-III Colon or Rectal Cancer, Phase III – Preventing Adenomas of the Colon with Eflornithine and Sulindac (PACES)." Dr. Zell. Activated: 3/1/13. Permanently Closed: 6/30/23

CTSU/A021502, "Randomized Trial of Standard Chemotherapy Alone or Combined with Atezolizumab as Adjuvant Therapy for Patients with Stage III Colon Cancer and Deficient DNA Mismatch Repair." Dr. Lieu. Activated: 9/12/17. Permanently Closed: 1/17/23

CTSU/A021703, "Randomized Double-Blind Phase III Trial of Vitamin D3 Supplementation in Patients with Previously Untreated Metastatic Colorectal Cancer (SOLARIS)." Dr. Cohen. Activated: 9/30/19. Permanently Closed: 12/15/22

Anal

Active Studies

A022104, "The Janus Rectal Cancer Trial: A Randomized Phase II Trial Testing the Efficacy of Triplet Versus Doublet Chemotherapy to Achieve Clinical Complete Response in Patients with Locally Advanced Rectal Cancer" Activated 11/9/22. SWOG Champion: A. Dasari

CTSU/EA2176, "Randomized Phase III Study of Immune Checkpoint Inhibition with Chemotherapy in Treatment-Naïve Metastatic Anal Cancer Patients." Dr. Morris. Activated: 10/15/20.

Gastrointestinal Committee

CTSU/EA2182, “A Randomized Phase II Study of De-Intensified ChemoRadiation for Early-Stage Anal Squamous Cell Carcinoma (DECREASE).” Dr. Murphy. Activated: 11/12/19.

CTSU/EA2201, “A Phase II Study of Neoadjuvant Nivolumab Plus Ipilimumab and Short-Course Radiation in MSI-H/dMMR Locally Advanced Rectal Adenocarcinoma.” Dr. Cho. Activated 5/13/21.

Other

Developing Studies

S2408, “A Randomized Phase III Blinded Trial of Lanreotide for the Prevention of Postoperative Pancreatic Fistula” Dr. Sham. Activating November 2024.

Publications

The publications listed below were received by the Group Chair’s Office as published (including online), accepted, or submitted since the SWOG Spring 2024 Group Meeting. Conference abstracts are not included.

Because of journal embargo policies, journal names are omitted for submitted or accepted manuscripts.

Published/Accepted Manuscripts

S1505 Body Composition Measurements and Clinical Outcomes in Patients with Resectable Pancreatic Adenocarcinoma: Analysis from SWOG S1505 [Brief Report]. Sohal D, Boutin R, Lenchik L, Kim J, Beg S, Wang-Gillam A, Wade J, Guthrie KA, Chiorean E, Ahmad S, Lowy A, Philip P, Chang V. *J Gastrointest Surg*. Mar;28(3):232-235, 2024. <https://pubmed.ncbi.nlm.nih.gov/38445914/>

S1505 Failure to Undergo Resection Following Neoadjuvant Therapy for Resectable Pancreatic Cancer: A Secondary Analysis of SWOG S1505. Cloyd J, Colby S, Guthrie KA, Lowy A, Chiorean E, Philip P, Sohal D, Ahmad S. *J Natl Compr Canc Netw* Apr 29:1-6. 2024. <https://pubmed.ncbi.nlm.nih.gov/38688309/>

A021501 Postoperative Adverse Events Following Neoadjuvant Therapy and Surgery in a Phase 2 Borderline Resectable Pancreatic Cancer Clinical Trial (Alliance A021501). Snyder R, Zemla T, Shi Q, Segovia D, Ahmad S, O’Reilly E, Herman J, Katz M. *Annals of Surgical Oncology* Jul 15. doi: 10.1245/s10434-024-15670-6. Online ahead of print, 2024. <https://pubmed.ncbi.nlm.nih.gov/39008208/>

A022104 Alliance A022104/NRG-GI010: The Janus Rectal Cancer Trial: a randomized phase II/III trial testing the efficacy of triplet versus doublet chemotherapy regarding clinical complete response and disease-free

survival in patients with locally advanced rectal cancer. Alvarez J, Shi Q, Dasari A, Garcia-Aguilar J, Sanoff H, George TJ, Hong TS, Yothers G, Philip PA, Nelson GD, Al Baghdadi T, Alese O, Zambare W, Omer DM, Verheij FS, Buckley J, Williams H, George M, Garcia R, O’Reilly EM, Meyerhardt JA, Shergill A, Horvat N, Romesser PB, Hall WA, Smith JJ. *BMC Cancer* Jul 26;24(1):901, 2024. <https://pubmed.ncbi.nlm.nih.gov/39060961/>

C80405 HER2 gene expression levels are predictive and prognostic in patients with metastatic colorectal cancer enrolled in CALGB/SWOG 80405. Battaglin F, Ou F, Qu X, Bertagnolli M, Hochster H, Niedzwiecki D, Goldberg R, Mayer R, Ashouri K, Zemla T, Blanke CD, Venook A, Kabbarah O, Lenz H-J, Innocenti F. *Journal of Clinical Oncology* Jun 1;42(16):1890-1902, 2024. <https://pubmed.ncbi.nlm.nih.gov/38457761/>

C80405 CCR5 and CCL5 gene expression in colorectal cancer: comprehensive profiling and clinical value. Battaglin F, Baca Y, Millstein J, Xiu J, Arai Y, Wang J, Ou F, Innocenti F, Jayachandran P, Kawanishi N, Lenz A, Soni S, Algaze S, Zhang W, Yang Y, Seeber A, Abraham J, Lou E, Philip PA, Weinberg B, Shields AF, Goldberg R, Marshall J, Venook A, Korn W, Lenz H-J. *Journal of Immunotherapy of Cancer* Jan 11;12(1):e007939, 2024. <https://pubmed.ncbi.nlm.nih.gov/38212126/>

C80405 DNA Mutational Profiling in Patients With Colorectal Cancer Treated With Standard of Care Reveals Differences in Outcome and Racial Distribution of Mutations. Innocenti F, Mu W, Qu X, Ou FS, Kabbarah O, Blanke CD, Venook AP, Lenz HJ, Rashid NU. *Journal of Clinical Oncology* Feb 1;42(4):399-409, 2024. <https://pubmed.ncbi.nlm.nih.gov/37992266/>

C80405 q-Diffusion leverages the full dimensionality of gene coexpression in single-cell transcriptomics. Marmarelis M, Singh N, Littman R, Battaglin F, Ambite J, Galstyan A, Lenz H-J, Ver Steeg G. *Communications Biology* Apr 2;7(1):400, 2024. <https://pubmed.ncbi.nlm.nih.gov/38565955/>

C80702 Improved survival with adjuvant COX-2 inhibition in PIK3CA-activated stage III colon cancer. Nowak J, Twombly T, Ma C, Shi Q, Haruki K, Fujiyoshi K, Vayrynen J, Zhao M, Knight J, Mane S, Kumar P, Couture F, Kuebler P, Krishnamurthi S, Tan B, Philip P, O’Reilly E, Shields A, Ogino S, Fuchs C, Meyerhardt J. *Journal of Clinical Oncology* Jun 18;42(24):3016-3024. doi: 10.1200/JCO.2023.01680. Online ahead of print, 2024. <https://pubmed.ncbi.nlm.nih.gov/38889377/>

C80702/Other Oxaliplatin-Based Adjuvant Chemotherapy in Older Patients With Stage III Colon Cancer: An ACCENT/IDEA Pooled Analysis of 12 Trials. Gallois C, Shi Q, Pederson LD, André T, Iveson TJ, Sobrero

Gastrointestinal Committee

AF, Alberts S, de Gramont A, Meyerhardt JA, George T, Schmoll HE, Souglakos I, Harkin A, Labianca R, Sinicrope FA, Oki E, Shields AF, Boukovinas I, Kerr R, Lonardi S, Yothers G, Yoshino T, Goldberg RM, Taieb J, Papamichael D. *Journal of Clinical Oncology* Jul 1;42(19):2295-2305, 2024. <https://pubmed.ncbi.nlm.nih.gov/38547438/>

Submitted Manuscripts

S1505 Chemotherapy Dose Density is Prognostic for Overall Survival in Patients with Resectable Pancreas Cancer: A Landmark Analysis of SWOG 1505. Patel S, Colby S, Sohal D, Guthrie K, Kachnic L, Chiorean EG, Lowy A, Rocha F, Hochster H, Philip P, Ahmad S. Submitted 2024.

S1613 Trastuzumab Plus Pertuzumab Versus Cetuximab Plus Irinotecan in Patient with RAS/BRAF wild-type, HER2-positive, Metastatic Colorectal Cancer(S1613): A Randomized Phase 2 Trial. Raghav K, Guthrie K, Tan B, Denlinger C, Fakih M, Overman M, Dasari NA, Corum L, Hicks L, Patel M, Esparaz B, Kazmi S, Alluri N, Colby S, Gholami S, Gold P, Chiorean EG, Kopetz ES, Hochster H, Philip PA. Submitted 2024.

S1815 SWOG S1815: A Phase III Randomized Trial of Gemcitabine, Cisplatin, and Nab-Paclitaxel versus Gemcitabine and Cisplatin in Newly Diagnosed, Advanced Biliary Tract Cancers (SWOG S1815; NCT#03768414). Shroff R, King G, Colby S, Scott A, Borad M, Matin K, Mahipal A, Kalyan A, Javle M, El Dika I, Tan B, Cheema P, Patel A, Iyer R, Kelley R, Thumar J, El-Khoueiry A, Guthrie K, Chiorean EG, Hochster H, Philip P. Submitted 2024.

S0809 The Effect of Radiation Modality on Outcomes of Patients Receiving Adjuvant Chemoradiotherapy for Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma: A Secondary Analysis of SWOG S0809. Horowitz D, Colby S, Gholami S, Guthrie KA, Ben-Josef E, El-Khoueiry A, Blanke CD, Philip P, Chiorean E, Rocha F, Ahmad S, Kachnic L. Submitted/in revision 2024.

N0147 Cetuximab reduces patient quality of life when administered with mFOLFOX6 as adjuvant treatment following complete resection of KRAS wild-type tumors for stage III colorectal cancer (N0147 Alliance). Mahoney MR, Sloan JA, Hubbard JM, Tan AD, Liu H, Goldberg RM, Nair SG, Shields AF, Gill S, Jahagirdar B, Benson A, Sargent DJ, Alberts SR. Submitted 2024.

Gastrointestinal Committee

Accrual from trials that are open as of 6/30/2024 or have closed in the prior 18 Months by Institution and Study

	S1922	S2001	S2104	S2107	S2303	A021502	A021602	A021806	A022001	A022102
Ascension Providence Hospitals - Southfield	-	2	-	-	-	3	-	-	-	-
Banner University Medical Center - Tucson	-	-	6	-	-	2	3	1	-	-
Baptist Mem Health Care/Mid South Minority Underserved NCORP	-	2	-	-	-	-	-	-	-	-
Baylor College of Medicine/Duncan Comprehensive Cancer Center	-	-	-	-	-	-	-	-	-	-
Boston Medical Center	-	-	-	-	-	1	3	1	-	3
CWRU Case Comprehensive Cancer Center LAPS	-	-	-	-	-	6	-	2	-	-
Cancer Research Consortium of West Michigan NCORP	-	-	-	2	-	-	-	-	-	-
Cancer Research for the Ozarks NCORP	-	1	-	-	-	-	-	-	-	-
Cancer Research of Wisconsin and Northern Michigan Consortium	-	-	-	-	1	-	-	-	-	-
Carle Cancer Center NCI Community Oncology Research Program	1	-	1	1	-	-	-	-	-	-
City of Hope Comprehensive Cancer Center	-	4	-	-	-	-	1	-	-	-
Columbia University Minority Underserved NCORP	-	1	-	-	-	-	-	-	-	-
CommonSpirit Health Research Institute	-	-	1	2	-	-	-	-	-	-
Corewell Health William Beaumont University Hospital	-	-	-	-	-	1	-	-	-	-
Dayton NCI Community Oncology Research Program	-	-	-	-	-	3	-	-	-	-
Fred Hutchinson Cancer Research Center LAPS	-	-	2	-	-	4	-	2	-	-
Gulf South Minority Underserved NCORP	-	-	-	3	-	-	-	-	-	-
Hawaii Minority Underserved NCORP	-	-	-	-	-	-	-	-	-	-
Heartland Cancer Research NCORP	1	1	-	3	-	-	-	-	-	-
Henry Ford Hospital	-	1	-	-	-	-	-	-	-	-
Houston Methodist Hospital	-	-	-	-	-	-	-	-	-	-
Kaiser Permanente NCI Community Oncology Research Program	-	-	-	5	-	17	-	-	-	-
Loma Linda University Medical Center	-	-	-	-	-	-	-	-	-	-
Medical University of South Carolina Minority Underserved NCORP	-	-	1	-	-	-	-	-	-	-
Michigan Cancer Research Consortium NCORP	1	2	-	3	-	-	-	-	-	-
Moffitt Cancer Center	-	-	2	-	-	-	4	-	-	-
Montana Cancer Consortium NCORP	-	-	-	1	-	-	-	-	-	-
NCORP of the Carolinas (Prisma Health NCORP)	-	-	1	-	-	-	-	-	-	-
Northwell Health NCORP	-	-	-	-	-	-	-	1	-	-
Northwestern University LAPS	1	-	-	-	-	1	-	1	-	-
Ohio State University Comprehensive Cancer Center LAPS	-	-	1	-	-	-	-	-	-	-

Gastrointestinal Committee

Accrual from trials that are open as of 6/30/2024 or have closed in the prior 18 Months by Institution and Study

	S1922	S2001	S2104	S2107	S2303	A021502	A021602	A021806	A022001	A022102
Oregon Health and Science University	-	-	1	-	-	-	-	-	-	-
Pacific Cancer Research Consortium NCORP	-	1	2	2	-	-	-	-	-	-
STCC at DHR Health Institute for Research and Development	-	-	-	-	-	-	-	-	-	-
Southeast Clinical Oncology Research Consortium NCORP	-	2	4	4	-	-	-	-	-	-
Sutter Cancer Research Consortium	-	-	-	-	-	3	-	-	-	-
The Don and Sybil Harrington Cancer Center	-	-	-	-	-	-	-	2	-	-
The West Clinic - Wolf River	-	-	-	-	-	-	-	-	-	-
UC Davis Comprehensive Cancer Center LAPS	-	-	-	-	-	4	-	-	-	-
UC Irvine Health/Chao Family Comprehensive Cancer Center	-	2	-	2	-	-	-	-	-	3
USC Norris Comprehensive Cancer Center LAPS	-	-	1	-	-	2	-	-	-	-
U of Alabama at Birmingham/Deep South Research Consortium LAPS	-	-	-	-	-	-	-	-	-	1
University of Arkansas for Medical Sciences	-	-	-	-	-	-	-	-	-	-
University of Cincinnati Cancer Center-UC Medical Center	-	-	1	-	-	-	-	-	-	-
University of Colorado Cancer Center LAPS	-	2	-	6	-	6	-	-	-	-
University of Kansas Cancer Center - MCA Rural MU NCORP	-	-	-	-	-	3	-	-	-	5
University of Kentucky/Markey Cancer Center	-	-	3	-	-	-	-	-	-	-
University of Michigan Comprehensive Cancer Center LAPS	3	3	1	-	-	-	4	4	-	-
University of Oklahoma Health Sciences Center LAPS	-	-	-	-	-	-	-	-	-	-
University of Rochester LAPS	1	-	-	-	-	2	8	11	-	1
University of Texas Health Science Center at San Antonio	-	-	-	-	-	-	-	3	-	-
University of Texas MD Anderson Cancer Center LAPS	11	-	-	8	-	-	-	-	-	-
University of Utah - Huntsman Cancer Institute LAPS	-	1	3	-	-	-	-	-	1	-
Vanderbilt University - Ingram Cancer Center LAPS	-	4	-	1	-	-	-	-	-	-
Virginia Mason Medical Center	-	-	-	-	-	4	2	-	-	-
Wayne State University - Karmanos Cancer Institute LAPS	-	1	-	-	-	2	-	-	-	2
Wisconsin NCI Community Oncology Research Program	-	-	1	1	-	-	-	-	-	-
Yale University - Yale Cancer Center LAPS	-	-	-	-	-	4	-	2	1	-
ALLIANCE	10	5	3	7	-	-	-	-	-	-
ECOG-ACRIN	2	11	5	11	-	-	-	-	-	-
NRG	3	5	7	7	-	-	-	-	-	-
Total	34	51	47	69	1	68	25	30	2	15

Gastrointestinal Committee

Accrual from trials that are open as of 6/30/2024 or have closed in the prior 18 Months by Institution and Study

	A022104	CCTGC032	CCTGNE1	EA2174	EA2176	EA2182	EA2186	EA2187	EA2192
Ascension Providence Hospitals - Southfield	-	-	-	-	1	2	2	-	-
Banner University Medical Center - Tucson	-	-	-	-	-	-	-	-	-
Baptist Memorial Health Care/Mid South Minority Underserved NCORP	-	-	-	-	-	-	-	-	-
Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center	4	-	-	-	-	-	-	-	-
Boston Medical Center	5	-	-	2	-	2	-	-	-
CWRU Case Comprehensive Cancer Center LAPS	-	-	-	2	-	4	1	3	-
Cancer Research Consortium of West Michigan NCORP	-	-	-	-	-	-	-	-	-
Cancer Research for the Ozarks NCORP	-	-	-	-	-	-	-	-	-
Cancer Research of Wisconsin and Northern Michigan Consortium	-	-	-	-	-	-	-	-	-
Carle Cancer Center NCI Community Oncology Research Program	-	-	-	-	-	-	-	-	-
City of Hope Comprehensive Cancer Center	-	-	-	-	-	-	3	-	-
Columbia University Minority Underserved NCORP	-	-	-	-	-	-	-	-	-
CommonSpirit Health Research Institute	-	-	-	-	-	-	-	-	-
Corewell Health William Beaumont University Hospital	-	-	-	-	-	-	-	-	-
Dayton NCI Community Oncology Research Program	-	-	-	-	-	-	1	-	-
Fred Hutchinson Cancer Research Center LAPS	6	-	-	-	-	-	1	-	-
Gulf South Minority Underserved NCORP	-	-	-	-	-	-	-	-	-
Hawaii Minority Underserved NCORP	-	-	-	-	-	-	2	-	-
Heartland Cancer Research NCORP	-	-	-	-	-	-	-	-	-
Henry Ford Hospital	-	-	-	-	-	-	-	-	-
Houston Methodist Hospital	-	-	-	-	-	-	-	-	-
Kaiser Permanente NCI Community Oncology Research Program	-	-	-	-	6	-	-	-	-
Loma Linda University Medical Center	-	-	-	-	-	-	-	-	-
Medical University of South Carolina Minority Underserved NCORP	-	-	-	-	-	-	-	-	-
Michigan Cancer Research Consortium NCORP	-	-	-	-	-	-	-	-	-
Moffitt Cancer Center	-	-	-	-	-	-	-	-	-
Montana Cancer Consortium NCORP	-	-	-	-	-	-	-	-	-
NCORP of the Carolinas (Prisma Health NCORP)	-	-	-	-	-	-	-	-	-
Northwell Health NCORP	-	-	-	1	-	-	2	-	-
Northwestern University LAPS	-	-	-	-	1	-	1	-	-
Ohio State University Comprehensive Cancer Center LAPS	-	-	-	-	-	-	-	-	-

Gastrointestinal Committee

Accrual from trials that are open as of 6/30/2024 or have closed in the prior 18 Months by Institution and Study

	A022104	CCTGC032	CCTGNE1	EA2174	EA2176	EA2182	EA2186	EA2187	EA2192
Oregon Health and Science University	-	-	-	-	4	1	-	-	2
Pacific Cancer Research Consortium NCORP	-	-	-	-	-	-	-	-	-
STCC at DHR Health Institute for Research and Development	-	-	-	-	-	-	-	-	-
Southeast Clinical Oncology Research Consortium NCORP	-	-	-	-	-	-	-	-	-
Sutter Cancer Research Consortium	-	-	-	-	-	-	-	1	-
The Don and Sybil Harrington Cancer Center	1	-	-	-	-	-	-	-	-
The West Clinic - Wolf River	11	-	-	-	-	-	-	-	-
UC Davis Comprehensive Cancer Center LAPS	1	-	-	-	-	-	-	-	-
UC Irvine Health/Chao Family Comprehensive Cancer Center	4	1	-	-	4	1	2	-	-
USC Norris Comprehensive Cancer Center LAPS	-	-	-	1	2	-	-	-	-
University of Alabama at Birmingham/Deep South Research Consortium LAPS	-	-	-	-	-	-	-	-	-
University of Arkansas for Medical Sciences	-	-	-	-	2	-	-	-	-
University of Cincinnati Cancer Center-UC Medical Center	-	-	-	-	1	1	-	-	-
University of Colorado Cancer Center LAPS	-	-	1	-	-	2	1	-	-
University of Kansas Cancer Center - MCA Rural MU NCORP	-	-	-	-	-	-	-	1	-
University of Kentucky/Markey Cancer Center	-	-	-	-	-	-	-	-	-
University of Michigan Comprehensive Cancer Center LAPS	1	-	-	-	-	-	-	-	-
University of Oklahoma Health Sciences Center LAPS	-	-	-	-	-	-	-	-	-
University of Rochester LAPS	13	-	-	-	-	-	7	2	-
University of Texas Health Science Center at San Antonio	4	-	-	-	-	-	3	-	-
University of Texas MD Anderson Cancer Center LAPS	-	-	-	-	10	-	-	-	-
University of Utah - Huntsman Cancer Institute LAPS	-	-	-	-	-	-	-	-	-
Vanderbilt University - Ingram Cancer Center LAPS	8	-	-	-	-	-	-	-	-
Virginia Mason Medical Center	3	-	-	-	-	-	-	-	-
Wayne State University - Karmanos Cancer Institute LAPS	-	-	-	-	-	1	-	-	-
Wisconsin NCI Community Oncology Research Program	-	-	-	-	-	-	-	-	-
Yale University - Yale Cancer Center LAPS	-	-	-	-	-	-	-	-	-
ALLIANCE	-	-	-	-	-	-	-	-	-
ECOG-ACRIN	-	-	-	-	-	-	-	-	-
NRG	-	-	-	-	-	-	-	-	-
Total	61	1	1	6	31	14	26	7	2

Gastrointestinal Committee

Accrual from trials that are open as of 6/30/2024 or have closed in the prior 18 Months by Institution and Study

	EA2197	EA2222	NRGGI004	NRGGI005	NRGGI006	NRGGI008
Ascension Providence Hospitals - Southfield	-	-	-	5	-	1
Banner University Medical Center - Tucson	-	-	-	-	-	-
Baptist Memorial Health Care/Mid South Minority Underserved NCORP	-	-	-	3	-	1
Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center	-	-	-	-	-	1
Boston Medical Center	-	-	-	-	-	-
CWRU Case Comprehensive Cancer Center LAPS	-	-	-	-	-	-
Cancer Research Consortium of West Michigan NCORP	-	-	-	-	-	-
Cancer Research for the Ozarks NCORP	-	-	-	-	-	-
Cancer Research of Wisconsin and Northern Michigan Consortium	-	-	-	-	-	-
Carle Cancer Center NCI Community Oncology Research Program	-	-	-	-	-	-
City of Hope Comprehensive Cancer Center	-	-	-	-	-	-
Columbia University Minority Underserved NCORP	-	-	-	-	-	-
CommonSpirit Health Research Institute	-	-	-	-	-	-
Corewell Health William Beaumont University Hospital	-	-	-	-	-	-
Dayton NCI Community Oncology Research Program	-	-	-	1	-	-
Fred Hutchinson Cancer Research Center LAPS	-	-	-	-	-	-
Gulf South Minority Underserved NCORP	-	-	-	-	-	-
Hawaii Minority Underserved NCORP	-	-	-	-	-	-
Heartland Cancer Research NCORP	-	-	-	-	-	-
Henry Ford Hospital	-	-	-	1	-	-
Houston Methodist Hospital	-	-	1	-	-	-
Kaiser Permanente NCI Community Oncology Research Program	-	-	-	11	-	-
Loma Linda University Medical Center	-	-	-	-	-	1
Medical University of South Carolina Minority Underserved NCORP	-	-	-	-	-	-
Michigan Cancer Research Consortium NCORP	-	-	-	1	-	-
Moffitt Cancer Center	-	-	-	-	-	-
Montana Cancer Consortium NCORP	-	-	-	-	-	-
NCORP of the Carolinas (Prisma Health NCORP)	-	-	-	-	-	-
Northwell Health NCORP	-	-	-	1	-	1
Northwestern University LAPS	-	-	-	-	-	-
Ohio State University Comprehensive Cancer Center LAPS	-	-	-	-	-	-

Gastrointestinal Committee

Accrual from trials that are open as of 6/30/2024 or have closed in the prior 18 Months by Institution and Study

	EA2197	EA2222	NRGGI004	NRGGI005	NRGGI006	NRGGI008
Oregon Health and Science University	4	-	-	1	-	-
Pacific Cancer Research Consortium NCORP	-	-	-	-	-	-
STCC at DHR Health Institute for Research and Development	-	-	-	1	-	-
Southeast Clinical Oncology Research Consortium NCORP	-	-	-	-	-	-
Sutter Cancer Research Consortium	-	-	-	-	-	-
The Don and Sybil Harrington Cancer Center	-	-	-	-	-	-
The West Clinic - Wolf River	-	-	-	-	-	2
UC Davis Comprehensive Cancer Center LAPS	1	-	-	1	-	-
UC Irvine Health/Chao Family Comprehensive Cancer Center	-	-	-	1	-	-
USC Norris Comprehensive Cancer Center LAPS	-	-	-	-	-	-
U of Alabama at Birmingham / Deep South Research Consortium LAPS	-	-	-	-	-	-
University of Arkansas for Medical Sciences	-	-	-	-	-	-
University of Cincinnati Cancer Center-UC Medical Center	-	-	-	-	-	-
University of Colorado Cancer Center LAPS	-	-	-	-	-	5
University of Kansas Cancer Center - MCA Rural MU NCORP	-	-	-	2	-	-
University of Kentucky/Markey Cancer Center	-	-	-	-	-	-
University of Michigan Comprehensive Cancer Center LAPS	-	1	-	-	-	-
University of Oklahoma Health Sciences Center LAPS	-	-	-	-	1	1
University of Rochester LAPS	-	-	1	-	-	5
University of Texas Health Science Center at San Antonio	-	-	-	-	-	-
University of Texas MD Anderson Cancer Center LAPS	-	-	13	1	-	-
University of Utah - Huntsman Cancer Institute LAPS	-	-	-	-	-	-
Vanderbilt University - Ingram Cancer Center LAPS	-	-	-	1	-	3
Virginia Mason Medical Center	1	-	-	-	-	-
Wayne State University - Karmanos Cancer Institute LAPS	-	-	-	-	-	-
Wisconsin NCI Community Oncology Research Program	-	-	-	-	-	-
Yale University - Yale Cancer Center LAPS	-	-	-	4	-	-
ALLIANCE	-	-	-	-	-	-
ECOG-ACRIN	-	-	-	-	-	-
NRG	-	-	-	-	-	-
Total	6	1	15	35	1	21

